13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002054410
Total reported value
$366.5M
$366.5M
21 檔
55.4%
As reported in its official Q4 2025 Form 13F filing, Acorn Capital Advisors, LLC's tracked investment portfolio stood at $366.5M with 21 total positions.
In Q4 2025, Acorn Capital Advisors, LLC displayed an active expansion posture, initiating 1 new positions and adding to 4 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 23.90% | -26.17% | EXIT | |
| 2 | CGON | Cg Oncology Inc | Stock-Other | 15.92% | +0.17% | — | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 11.49% | +8.25% | +14.98% | |
| 4 | TRVI | Trevi Therapeutics Inc | Stock-Other | 9.10% | +3.65% | — | |
| 5 | PBYI | Puma Biotechnology Inc | Stock-Other | 8.33% | +1.64% | — | |
| 6 | CADL | Candel Therapeutics Inc | Stock-Other | 4.94% | +4.94% | — | |
| 7 | HELP | Cybin Inc | Stock-Other | 4.36% | +0.68% | +114.19% | |
| 8 | VSTM | Verastem Inc | Stock-Other | 3.84% | -0.68% | +88.47% | |
| 9 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.67% | +1.57% | — | |
| 10 | TARA | Protara Therapeutic Inc | Stock-Other | 3.16% | -0.76% | — | |
| 11 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 2.79% | +0.19% | — | |
| 12 | CRDF | Cardiff Oncology Inc | Stock-Other | 1.87% | -0.81% | EXIT | |
| 13 | LONA | Leonabio Inc | Stock-Other | 1.29% | -0.26% | — | |
| 14 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.11% | -0.19% | +29.21% | |
| 15 | AURA | Aura Biosciences Inc | Stock-Other | 1.10% | +0.67% | — | |
| 16 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.93% | +0.30% | — | |
| 17 | BCABGBP | Bioatla Inc | Stock-Other | 0.93% | -0.13% | — | |
| 18 | QTTB | Q32 Bio Inc | Stock-Other | 0.56% | +0.18% | -38.58% | |
| 19 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.37% | -0.27% | EXIT | |
| 20 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.33% | — | — | |
| 21 | VYNE | Vyne Therapeutics Inc | Stock-Other | — | — | -99.76% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | +16.4% | -11.41% | Trim |
| 2 | HELP | Cybin Inc | +2.2% | +114.19% | Add |
| 3 | VSTM | Verastem Inc | +0.4% | +88.47% | Add |
| 4 | ACRV | Acrivon Therapeutics Inc | 0% | — | Unchanged |
| 5 | VYNE | Vyne Therapeutics Inc | -0.1% | -99.76% | Trim |
| 6 | ASNSUSD | X4 Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 7 | WHWK | Whitehawk Therapeutics Inc | -0.2% | — | Unchanged |
| 8 | CRDF | Cardiff Oncology Inc | -0.2% | — | Unchanged |
| 9 | QTTB | Q32 Bio Inc | -0.3% | -38.58% | Trim |
| 10 | JSPR | Jasper Therapeutics Inc | -0.6% | +29.21% | Add |
| 11 | TARA | Protara Therapeutic Inc | -0.7% | — | Unchanged |
| 12 | BCABGBP | Bioatla Inc | -0.8% | — | Unchanged |
| 13 | AURA | Aura Biosciences Inc | -0.8% | — | Unchanged |
| 14 | TRVI | Trevi Therapeutics Inc | -0.9% | — | Unchanged |
| 15 | OKUR | Onkure Therapeutics Inc-a | -1.2% | — | Unchanged |
| 16 | URGN | UroGen Pharma Ltd. | -1.3% | +14.98% | Add |
| 17 | BCAX | Bicara Therapeutics Inc | -1.5% | — | Unchanged |
| 18 | CADL | Candel Therapeutics Inc | -1.7% | — | Unchanged |
| 19 | PBYI | Puma Biotechnology Inc | -2.8% | — | Unchanged |
| 20 | CGON | Cg Oncology Inc | -7.2% | — | Unchanged |
| 21 | LONA | Leonabio Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Acorn Capital Advisors, LLC reported a total U.S. public equity portfolio value of $366.5M across 21 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, CGON, URGN) accounted for 55.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
LONA
市值: $3.8M
Top Position Liquidated / Trimmed
430
前期市值: $14.8M
During Q4 2025, Acorn Capital Advisors, LLC's top holdings by market value included 430 (23.9%)、CGON (15.9%)、URGN (11.5%). The largest single position, 430, represented 23.9% of total portfolio value.
In Q4 2025, Acorn Capital Advisors, LLC made 8 total portfolio adjustments, initiating 1 new buys, adding to 4 positions, trimming 3 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.